2017年3月10日, 國際著名學術雜誌《Cell》子刊《Cell Chemical Biology》雜誌線上發表了中國科學院動物研究所王宇研究組撰寫了題為Hedgehog Signaling: From Basic Biology to Cancer Therapy 的綜述文章。 王宇組研究生吳付佳為第一作者, 通訊作者為王宇研究員。
Hedgehog信號通路是某些成體幹細胞和腫瘤幹細胞的核心信號通路之一, 它的異常可導致多種退行性病變和癌症。 自1980年Hedgehog信號通路被發現和命名以來, 歷經數十年的探索、研究和開發, 針對Hedgehog的靶向抗癌藥vismodegib和sonidegib已分別於2012年和2015年被美國FDA批准。 因此, Hedgehog通路是從基礎研究走向臨床應用的成功案例之一。
小分子調控機制的研究, 尤其是面向Hedgehog通路這類重要靶點的研究,
Hedgehog信號通路內源小分子調控機制的假說模型
原文連結:
原文摘要:
The Hedgehog (HH) signaling pathway was discovered originally as a key pathway in embryonic patterning and development. Since its discovery, it has become increasingly clear that the HH pathway also plays important roles in a multitude of cancers. Therefore, HH signaling has emerged as a therapeutic target of interest for cancer therapy. In this review, we provide a brief overview of HH signaling and the key molecular players involved and offer an up-to-date summary of our current knowledge of endogenous and exogenous small molecules that modulate HH signaling. We discuss experiences and lessons learned from the decades-long efforts toward the development of cancer therapies targeting the HH pathway. Challenges to develop next-generation cancer therapies are highlighted.